Suppr超能文献

加纳耐药结核病负担;第一次全国调查结果。

The burden of drug resistance tuberculosis in Ghana; results of the First National Survey.

机构信息

Department of Theoretical and Applied Biology, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

出版信息

PLoS One. 2021 Jun 10;16(6):e0252819. doi: 10.1371/journal.pone.0252819. eCollection 2021.

Abstract

Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cases. We also evaluated associations between potential risk factors and TB drug resistance. Using the World Health Organization (WHO) guidelines on conducting national TB surveys, we selected study participants from 33 health facilities from across the country, grouped into 29 clusters, and included them into the survey. Between April 2016 and June 2017, a total of 927 patients (859 new and 68 previously treated) were enrolled in the survey. Mycobacterium tuberculosis complex (MTBC) isolates were successfully cultured from 598 (65.5%) patient samples and underwent DST, 550 from newly diagnosed and 48 from previously treated patients. The proportion of patients who showed resistance to any of the TB drugs tested was 25.2% (95% CI; 21.8-28.9). The most frequent resistance was to Streptomycin (STR) (12.3%), followed by Isoniazid (INH) (10.4%), with Rifampicin (RIF), showing the least resistance of 2.4%. Resistance to Isoniazid and Rifampicin (multi-drug resistance) was found in 19 (3.2%; 95% CI: 1.9-4.9) isolates. Prevalence of multidrug resistance was 7 (1.3%; 95% CI: 0.5-2.6) among newly diagnosed and 12 (25.0%; 95% CI: 13.6-39.6) among previously treated patients. At both univariate and multivariate analysis, MDR-TB was positively associated with previous history of TB treatment (OR = 5.09, 95% CI: 1.75-14.75, p = 0.003); (OR = 5.41, 95% CI: 1.69-17.30, p = 0.004). The higher levels of MDR-TB and overall resistance to any TB drug among previously treated patients raises concerns about adherence to treatment. This calls for strengthening existing TB programme measures to ensure a system for adequately testing and monitoring TB drug resistance.

摘要

抗结核药物耐药性已成为全球结核病(TB)控制的主要威胁。我们进行了首次全国范围的耐药性调查,以调查新的和以前治疗过的痰涂片阳性肺结核病例中一线抗结核药物的耐药水平和模式。我们还评估了潜在危险因素与结核病药物耐药性之间的关联。我们使用世界卫生组织(WHO)关于进行国家结核病调查的指南,从全国 33 个卫生机构中选择研究参与者,将其分为 29 个组,并将其纳入调查。2016 年 4 月至 2017 年 6 月,共有 927 名(859 名新诊断和 68 名以前治疗过)患者参加了该调查。从 598 名(新诊断的 550 名和以前治疗过的 48 名)患者的样本中成功培养出结核分枝杆菌复合体(MTBC)分离株,并进行了药敏试验。对任何一种测试的抗结核药物显示耐药的患者比例为 25.2%(95%CI;21.8-28.9)。最常见的耐药性是链霉素(STR)(12.3%),其次是异烟肼(INH)(10.4%),而利福平(RIF)的耐药性最低,为 2.4%。发现对异烟肼和利福平(耐多药)的耐药性在 19 株(3.2%;95%CI:1.9-4.9)分离株中。新诊断的耐多药结核病的患病率为 7 例(1.3%;95%CI:0.5-2.6),而以前治疗过的患者的患病率为 12 例(25.0%;95%CI:13.6-39.6)。在单变量和多变量分析中,耐多药结核病与以前的结核病治疗史呈正相关(OR=5.09,95%CI:1.75-14.75,p=0.003);(OR=5.41,95%CI:1.69-17.30,p=0.004)。以前治疗过的患者中耐多药结核病和对任何抗结核药物的总体耐药性水平较高,令人担忧治疗的依从性。这就要求加强现有的结核病规划措施,以确保建立一个充分测试和监测结核病药物耐药性的系统。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c0e/8191906/6b48d15d9f9e/pone.0252819.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验